It is known that interleukin-17 (IL-17) is associated with autoimmune disorders and that peripheral IL-17 plays a role in arthritis and neuropathic pain. The present study investigated the possibility of spinal cell expression of IL-17 during inflammatory pain and possible IL-17 involvement in such pain. Hyperalgesia was induced by injecting complete Freund adjuvant (CFA, 0.08 mL, 40 lg Mycobacterium tuberculosis) into one hind paw of the rat. Paw withdrawal latency (PWL) was tested before (À48 h) and 2 and 24 h after CFA injection to assess hyperalgesia. IL-17 antibody (0.2-2 lg/rat) was given intrathecally (i.t.) 24 h before CFA to block the action of basal IL-17 and 2 h before each of 2 PWL tests to block CFA-induced IL-17. I.t. recombinant IL-17 (10-400 ng per rat) was administered to naive rats to determine its effects on PWL and phosphorylated NR1 (p-NR1). p-NR1 modulates N-methyl-D-aspartate receptor (NMDAR) activity to facilitate pain. Spinal cords were removed for IL-17 immunostaining, double immunostaining of IL-17/cell markers and IL-17 receptor A (IL-17RA)/NR1, for Western blot testing of IL-17, p-NR1, IL-17RA, and GFAP, for in situ IL-17RA hybridization, and for real time polymerase chain reaction of IL-17RA. The data reveal that IL-17 is up-regulated in activated and nonactivated astrocytes; that IL-17RA is localized in NR1-immunoreactive neurons and up-regulated; and that IL-17 antibody at 2 lg/rat significantly increased PWL (P < .05) and decreased p-NR1 and IL-17RA compared to control in CFA-and IL-17-injected rats. The results suggest that spinal IL-17 is produced by astrocytes and enhances p-NR1 to facilitate pain. Ó
t r a c t
It is known that interleukin-17 (IL-17) is associated with autoimmune disorders and that peripheral IL-17 plays a role in arthritis and neuropathic pain. The present study investigated the possibility of spinal cell expression of IL-17 during inflammatory pain and possible IL-17 involvement in such pain. Hyperalgesia was induced by injecting complete Freund adjuvant (CFA, 0.08 mL, 40 lg Mycobacterium tuberculosis) into one hind paw of the rat. Paw withdrawal latency (PWL) was tested before (À48 h) and 2 and 24 h after CFA injection to assess hyperalgesia. IL-17 antibody (0.2-2 lg/rat) was given intrathecally (i.t.) 24 h before CFA to block the action of basal IL-17 and 2 h before each of 2 PWL tests to block CFA-induced IL-17. I.t. recombinant IL-17 (10-400 ng per rat) was administered to naive rats to determine its effects on PWL and phosphorylated NR1 (p-NR1). p-NR1 modulates N-methyl-D-aspartate receptor (NMDAR) activity to facilitate pain. Spinal cords were removed for IL-17 immunostaining, double immunostaining of IL-17/cell markers and IL-17 receptor A (IL-17RA)/NR1, for Western blot testing of IL-17, p-NR1, IL-17RA, and GFAP, for in situ IL-17RA hybridization, and for real time polymerase chain reaction of IL-17RA. The data reveal that IL-17 is up-regulated in activated and nonactivated astrocytes; that IL-17RA is localized in NR1-immunoreactive neurons and up-regulated; and that IL-17 antibody at 2 lg/rat significantly increased PWL (P < .05) and decreased p-NR1 and IL-17RA compared to control in CFA-and IL-17-injected rats. The results suggest that spinal IL-17 is produced by astrocytes and enhances p-NR1 to facilitate pain.
Ó 2012 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Introduction
The interleukin-17 (IL-17) cytokine family has recently emerged as a critical player in immune system and inflammatory diseases. The family consists of 6 ligands (IL-17A-F) and 5 receptors (IL-17RA-IL-17RE) in mammals [6] . IL-17A, also known as IL-17, the prototypical IL-17 ligand, is mainly produced by a subset of CD 4+ T helper (TH) cells now known as TH-17 cells [29, 39] . These act on IL-17RA to up-regulate the expression of inflammatory genes such as IL-6, IL-8, granulocyte colony stimulating factor, and prostaglandin E2 in epithelial, endothelial, and fibroblastic cells [5] . It is well known that IL-17 is elevated in multiple sclerosis, rheumatoid arthritis, and psoriasis [11, 21] and is involved in these autoimmune disorders [18, 21, 30] . Recent studies have demonstrated that glial cells of the central nervous system also express IL-17. For example, IL-17 was produced in the astrocytes of rats with permanent middle cerebral artery occlusion [17] and in brain astrocytes of patients with multiple sclerosis [33] . It is also well known that glial cells, including astrocytes and microglia, are activated in the lumbar spinal cord in inflammatory [25, 32, 37] and neuropathic pain models [20, 24, 31] . Glial cells release a variety of algesic substances, including proinflammatory cytokines such as IL-1b, tumor necrosis factor alpha, and IL-6, which may potentiate transmission and processing of noxious inputs at the spinal level [25, 38] . Whether spinal glial cells produce IL-17 during inflammatory pain and whether IL-17 is involved in such pain have not been studied.
